Synonyms: VERU-111 | VERU111
Compound class:
Synthetic organic
Comment: Sabizabulin (VERU-111) is an orally bioavailable βIII/βIV-tubulin inhibitor that was developed for anti-tumour potential [1-2]. It interacts with the tubulin colchicine binding site. VERU-111 induces mitotic arrest and apoptosis in cancer cells in vitro, and inhibits xenograft tumour growth. It is suggested that like colchicine, VERU-111 may have anti-viral and anti-inflammatory actions in addition to its antiproliferative activity.
COVID-19: Sabizabulin has been repositioned as a potential therapeutic for COVID-19; in particular for patients who are hospitalised with moderate to severe COVID-19 and who are at high risk for developing acute respiratory distress syndrome (ARDS). |
|
No information available. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04388826 | COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111 | Phase 2 Interventional | Veru Inc. | ||
NCT03752099 | To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer | Phase 1/Phase 2 Interventional | Veru Inc. | ||
NCT04842747 | VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study | Phase 3 Interventional | Veru Inc. |